Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vitamin B, E health claims

This article was originally published in The Tan Sheet

Executive Summary

Stay of litigation in Whitaker v. Shalala extended until Feb. 9 as FDA continues to review proposed vitamin E/heart disease claim and the parties negotiate language for a qualified B vitamin/vascular disease claim. Plaintiff dietary supplement marketers and developers continue to insist a CDC statement recognizing elevated plasma homocysteine as an independent risk factor for vascular disease should be included in any B vitamin claim. Previous litigation stay expired Jan. 12 (1"The Tan Sheet" Dec. 18, 2000, p. 7)
Advertisement

Related Content

Vitamin B Health Claim Omits CDC Homocysteine Findings, Plaintiffs Say
Vitamin B Health Claim Omits CDC Homocysteine Findings, Plaintiffs Say

Topics

Advertisement
UsernamePublicRestriction

Register

PS092113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel